Lidocaine 3.5% · ophthalmic gel
Local Anesthetic
Approved uses
Ocular surface anesthesia for ophthalmologic procedures
2 drops to the ocular surface over the planned procedure site; may be reapplied to maintain effect
Anesthesia begins 20 seconds to 1 minute after instillation and lasts 5 to 30 minutes.
Anesthesia for intravitreal injection
2 drops to the ocular surface before injection, the labeled dose
No better than proparacaine drops for immediate pain at intravitreal injection.
Contraindications
None.
Lidocaine HCl 3.5% (35 mg/mL) preservative-free ophthalmic gel, 1 mL single-patient-use tube, cartons of 1 or 25 tubes
Amide local anesthetic that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Warnings & Precautions
- Topical ophthalmic use only: Not for injection or intraocular administration.
- Corneal injury from insensitivity: The eye must not be touched for at least 10 to 20 minutes after instillation, since accidental injury can occur while sensation is absent.
- Corneal opacification: Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
- Provider administration: Indicated for administration under the direct supervision of a healthcare provider, not for patient self-administration.
- Anesthetic abuse keratopathy: In a retrospective review of 19 patients with topical anesthetic abuse keratopathy, ring-shaped keratitis and hypopyon were among the findings, mean epithelization period was 19.96 days, and twelve patients (63.2%) continued using these agents during their hospitalization. A report of three patients concluded that abuse of topical anesthetic drops may masquerade as acanthamoeba keratitis.
Common Side Effects
The most common adverse reactions are conjunctival hyperemia, corneal epithelial changes, headache, and burning upon instillation. Topical ocular application is not expected to result in systemic exposure.
Pregnancy: No adequate and well-controlled studies in pregnant women; subcutaneous dosing in pregnant rats at more than 800 times the human dose on a body surface area basis produced no adverse developmental effects.
Lactation: Secreted in human milk; clinical significance unknown. Caution should be exercised when administered to a nursing woman.
Established in pediatric patients, extrapolated from adult trials and from pediatric studies of other lidocaine formulations.